Differential expression of an ensemble of the key genes involved in cell-cycle regulation in lung cancer
- Authors: Krasnov G.S.1, Puzanov G.A.1, Kudryavtseva A.V.1, Dmitriev A.A.1, Beniaminov A.D.1, Kondratieva T.T.2, Senchenko V.N.1
-
Affiliations:
- Engelhardt Institute of Molecular Biology
- Cancer Research Center
- Issue: Vol 51, No 5 (2017)
- Pages: 740-747
- Section: Molecular Cell Biology
- URL: https://journals.rcsi.science/0026-8933/article/view/163261
- DOI: https://doi.org/10.1134/S0026893317050107
- ID: 163261
Cite item
Abstract
Targeted cancer therapy directed at individual targets is often accompanied by the rapid development of drug resistance. The development of a new generation of antitumor drugs involves the search for many targets simultaneously to block or, conversely, restore their activity. In this regard, simultaneous analysis of gene expression in a complex network of interactions, primarily cell cycle control elements, is relevant for the search of specific molecular markers for the differential diagnosis of adenocarcinoma (ADC) and squamous cell lung cancer (SCC), as well as new targets for therapy. In this paper we performed an extended quantitative analysis of the expression of two suppressor genes, CTDSPL and its target RB1, as well as 84 genes of the main participants of the p16INK4A-Cdk/cyclin D1-Rb and p53/p21Waf1 signaling pathways in the histological types of non-small-cell lung cancer (NSCLC), i.e., ADC and SCC, using the special panel of the Human Cell Cycle Regulation Panel. The expression profile of some genes shows the specificity to the histological type of NSCLC and the presence of metastases. The genes with a significantly increased expression that affect the activity of Rb (cyclins, cyclin-dependent kinases, their activators, inhibitors, etc.) can serve as potential targets for combined therapy of both ADC and SCC.
About the authors
G. S. Krasnov
Engelhardt Institute of Molecular Biology
Email: versen@eimb.ru
Russian Federation, Moscow, 119991
G. A. Puzanov
Engelhardt Institute of Molecular Biology
Email: versen@eimb.ru
Russian Federation, Moscow, 119991
A. V. Kudryavtseva
Engelhardt Institute of Molecular Biology
Email: versen@eimb.ru
Russian Federation, Moscow, 119991
A. A. Dmitriev
Engelhardt Institute of Molecular Biology
Email: versen@eimb.ru
Russian Federation, Moscow, 119991
A. D. Beniaminov
Engelhardt Institute of Molecular Biology
Email: versen@eimb.ru
Russian Federation, Moscow, 119991
T. T. Kondratieva
Cancer Research Center
Email: versen@eimb.ru
Russian Federation, Moscow, 115478
V. N. Senchenko
Engelhardt Institute of Molecular Biology
Author for correspondence.
Email: versen@eimb.ru
Russian Federation, Moscow, 119991
Supplementary files
